Today: 30 April 2026
Intel stock price forecast: INTC jumps on 18A chip rollout as a $50 target re-enters view
7 January 2026
2 mins read

Intel stock price forecast: INTC jumps on 18A chip rollout as a $50 target re-enters view

New York, January 7, 2026, 15:29 EST — Regular session

  • Intel shares rise about 6% in afternoon trade, bucking a weaker semiconductor ETF tape.
  • The rally follows Intel’s CES launch of Core Ultra Series 3, its first consumer chips built on the 18A manufacturing node.
  • Melius Research turned bullish with a $50 target, but broader target averages cited in data feeds sit below the current share price.

Intel shares jumped 6.3% to $42.56 in afternoon trading on Wednesday, outpacing a slide in chip ETFs, as investors leaned into the company’s CES pitch that its new 18A manufacturing push is ready for prime time. The iShares Semiconductor ETF fell 1.2% and VanEck’s chip ETF slipped 0.7%, while the Nasdaq 100 ETF was modestly higher and the S&P 500 ETF edged down.

Why it matters now is credibility. Intel’s stock has become a referendum on whether it can execute its manufacturing roadmap after years of delays and missed windows, not just whether the PC market is growing.

18A is the shorthand investors keep coming back to — a new “process node,” or the production technology used to make chips smaller, faster and more power-efficient. If Intel can ramp it in volume, it strengthens the case that it can win back share from AMD and sell manufacturing services to outside customers, not just build its own parts.

Intel said its Core Ultra Series 3 processors are the first AI PC platform built on Intel 18A, and it expects systems to be available globally starting Jan. 27 after pre-orders began on Tuesday. Jim Johnson, a senior vice president who runs Intel’s Client Computing Group, said the company is “laser-focused on improving power efficiency” while adding “more AI compute.” Intel

At CES in Las Vegas, Intel rolled out the Panther Lake laptop line as the debut for its 18A process, a step it framed as a key proof point as it tries to regain ground lost to AMD. Chief executive Lip-Bu Tan said Intel had made good on its promise to ship its first products made on 18A in 2025, and Johnson described a “chiplet” design — smaller chips stitched together — including a separate graphics chiplet. Intel has struggled with yields on Panther Lake, Reuters reported, though executives have said those yields are improving month by month. Reuters

The near-term price debate sharpened after Melius Research upgraded Intel to “buy” and set a $50 price target, according to MarketBeat. That target sits about 17% above Wednesday’s price. In a separate commentary carried by MarketWatch, Melius analyst Ben Reitzes argued the stock remained “still a huge discount to TSMC.” MarketBeat+1

Other forecasts look less forgiving. Fintel data cited by Nasdaq put Intel’s average one-year price target at $37.52 as of Dec. 20, with estimates ranging from $18.18 to $54.60 — a spread that underlines how split views remain even after this week’s news.

From a trader’s point of view, Wednesday’s range tells the story: Intel has swung from $39.85 to $44.55 in the session. A clean break above that high would put the $50 analyst target back in play, while a slip back under the $40 area would test whether this week’s CES optimism is anything more than a pop.

But the risk case is easy to write. If yields stall, or if “AI PC” demand — laptops designed to run some AI features on-device — does not turn into orders and margins, the stock can give back gains quickly, especially with rivals still setting the pace in AI hardware.

What investors watch next is whether the CES launch turns into shipments and shelf space: Intel says systems using Core Ultra Series 3 start becoming available globally on Jan. 27. The next obvious checkpoint after that is Intel’s results, with the company’s earnings date listed as Jan. 29 on Yahoo Finance’s calendar.

Stock Market Today

  • FedEx Shares Look Undervalued Despite Strong Rally, DCF Model Suggests
    April 30, 2026, 3:52 PM EDT. FedEx (FDX) has gained nearly 89% over the past year, raising questions about further upside. However, a discounted cash flow (DCF) valuation model pegs FedEx's intrinsic value at approximately $811 per share, suggesting the stock is about 52% undervalued compared to its current price near $388. FedEx's free cash flow, projected to grow from $3.6 billion to $8.3 billion by 2029, underpins this optimistic valuation. Despite strong recent share price performance, investors may find value considering FedEx's pivotal role in global logistics and parcel delivery, sectors sensitive to e-commerce trends and shipping demand. The price-to-earnings (P/E) ratio and Simply Wall St's valuation score of 4 out of 6 further support this cautious optimism.

Latest article

Iron Mountain Stock Jumps as AI Data-Center Demand Pushes 2026 Forecast Higher

Iron Mountain Stock Jumps as AI Data-Center Demand Pushes 2026 Forecast Higher

30 April 2026
Iron Mountain raised its 2026 revenue outlook after first-quarter revenue jumped 21.6% to $1.94 billion and net income rose to $149 million from $16 million. Shares surged 10% to $125.93. Data center revenue climbed 47% to $255 million, while asset lifecycle management revenue nearly doubled to $232 million. The company now expects 2026 revenue of $7.825–$7.925 billion.
Rezolve AI Stock Rises After Revenue Tops All of 2025 in 90 Days

Rezolve AI Stock Rises After Revenue Tops All of 2025 in 90 Days

30 April 2026
Rezolve AI reported $60 million in first-quarter revenue, surpassing its audited 2025 total of $46.8 million, based on unaudited accounts. Shares rose 4.9% after the update. The company reaffirmed its $360 million 2026 revenue target and said it can reach profitability without new equity sales. Commerce.com, which rejected Rezolve’s all-stock takeover offer, adopted a poison pill defense.
Option Care Health Stock Plunges After 2026 Revenue Cut Exposes Chronic-Therapy Drag

Option Care Health Stock Plunges After 2026 Revenue Cut Exposes Chronic-Therapy Drag

30 April 2026
Option Care Health shares fell 28% to $19.44 after the company cut its 2026 revenue forecast and reported first-quarter sales of $1.35 billion, missing estimates. The company now expects 2026 revenue of $5.675–$5.775 billion, down from a prior range of $5.8–$6.0 billion, citing pressure in its chronic inflammatory disease portfolio. Adjusted profit guidance was unchanged.
Meta stock price forecast: China review of Manus deal drags META as Wall Street targets $822
Previous Story

Meta stock price forecast: China review of Manus deal drags META as Wall Street targets $822

Apple stock price forecast: AAPL slides as memory costs rise and earnings near
Next Story

Apple stock price forecast: AAPL slides as memory costs rise and earnings near

Go toTop